AK Medical Holdings Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Zhijiang Li
Algemeen directeur
CN¥1.1m
Totale compensatie
| Percentage CEO-salaris | 74.9% |
| Dienstverband CEO | 9.3yrs |
| Eigendom CEO | 45.0% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 8.8yrs |
Recente managementupdates
Recent updates
AK Medical Holdings Limited's (HKG:1789) Intrinsic Value Is Potentially 92% Above Its Share Price
Aug 30
Why We're Not Concerned Yet About AK Medical Holdings Limited's (HKG:1789) 25% Share Price Plunge
Jun 20It's Unlikely That Shareholders Will Increase AK Medical Holdings Limited's (HKG:1789) Compensation By Much This Year
Jun 11Returns On Capital At AK Medical Holdings (HKG:1789) Paint A Concerning Picture
May 27We Think AK Medical Holdings (HKG:1789) Can Stay On Top Of Its Debt
May 08Investors Appear Satisfied With AK Medical Holdings Limited's (HKG:1789) Prospects
Apr 21AK Medical Holdings Limited (HKG:1789) Analysts Are Reducing Their Forecasts For This Year
Apr 01AK Medical Holdings' (HKG:1789) Returns On Capital Not Reflecting Well On The Business
Jan 22Shareholders Should Be Pleased With AK Medical Holdings Limited's (HKG:1789) Price
Jan 04AK Medical Holdings (HKG:1789) Seems To Use Debt Rather Sparingly
Dec 12A Look At The Fair Value Of AK Medical Holdings Limited (HKG:1789)
Nov 09AK Medical Holdings (HKG:1789) Could Be Struggling To Allocate Capital
Sep 20AK Medical Holdings (HKG:1789) Could Easily Take On More Debt
Sep 03Investors Could Be Concerned With AK Medical Holdings' (HKG:1789) Returns On Capital
Jun 07Estimating The Fair Value Of AK Medical Holdings Limited (HKG:1789)
May 18Returns On Capital Signal Tricky Times Ahead For AK Medical Holdings (HKG:1789)
Feb 13Returns On Capital Signal Tricky Times Ahead For AK Medical Holdings (HKG:1789)
Nov 10Estimating The Fair Value Of AK Medical Holdings Limited (HKG:1789)
Sep 29Be Wary Of AK Medical Holdings (HKG:1789) And Its Returns On Capital
Aug 04Are Investors Undervaluing AK Medical Holdings Limited (HKG:1789) By 44%?
Jun 25There Are Reasons To Feel Uneasy About AK Medical Holdings' (HKG:1789) Returns On Capital
Apr 11Capital Allocation Trends At AK Medical Holdings (HKG:1789) Aren't Ideal
Oct 08Estimating The Intrinsic Value Of AK Medical Holdings Limited (HKG:1789)
Sep 20Analysts Are More Bearish On AK Medical Holdings Limited (HKG:1789) Than They Used To Be
Jul 27I Built A List Of Growing Companies And AK Medical Holdings (HKG:1789) Made The Cut
Jul 19AK Medical Holdings Limited (HKG:1789) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jun 16The Returns On Capital At AK Medical Holdings (HKG:1789) Don't Inspire Confidence
Jun 01AK Medical Holdings Limited (HKG:1789) Analysts Are More Bearish Than They Used To Be
Apr 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥189m |
| Mar 31 2024 | n/a | n/a | CN¥185m |
| Dec 31 2023 | CN¥1m | CN¥814k | CN¥182m |
| Sep 30 2023 | n/a | n/a | CN¥197m |
| Jun 30 2023 | n/a | n/a | CN¥211m |
| Mar 31 2023 | n/a | n/a | CN¥208m |
| Dec 31 2022 | CN¥972k | CN¥806k | CN¥205m |
| Sep 30 2022 | n/a | n/a | CN¥156m |
| Jun 30 2022 | n/a | n/a | CN¥107m |
| Mar 31 2022 | n/a | n/a | CN¥100m |
| Dec 31 2021 | CN¥913k | CN¥800k | CN¥93m |
| Sep 30 2021 | n/a | n/a | CN¥178m |
| Jun 30 2021 | n/a | n/a | CN¥263m |
| Mar 31 2021 | n/a | n/a | CN¥288m |
| Dec 31 2020 | CN¥524k | CN¥430k | CN¥314m |
| Sep 30 2020 | n/a | n/a | CN¥307m |
| Jun 30 2020 | n/a | n/a | CN¥300m |
| Mar 31 2020 | n/a | n/a | CN¥284m |
| Dec 31 2019 | CN¥1m | CN¥779k | CN¥267m |
| Sep 30 2019 | n/a | n/a | CN¥235m |
| Jun 30 2019 | n/a | n/a | CN¥203m |
| Mar 31 2019 | n/a | n/a | CN¥174m |
| Dec 31 2018 | CN¥1m | CN¥764k | CN¥145m |
| Sep 30 2018 | n/a | n/a | CN¥136m |
| Jun 30 2018 | n/a | n/a | CN¥127m |
| Mar 31 2018 | n/a | n/a | CN¥116m |
| Dec 31 2017 | CN¥776k | CN¥765k | CN¥105m |
Compensatie versus markt: De totale vergoeding ($USD 152.64K ) Zhijiang } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 495.13K ).
Compensatie versus inkomsten: De vergoeding van Zhijiang is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Zhijiang Li (56 yo)
9.3yrs
Tenure
CN¥1,087,000
Compensatie
Mr. Zhijiang Li serves as Chairman and Chief Executive Officer at AK Medical Holdings Limited. Mr. Li is responsible for the overall strategic planning and development of at AK Medical Holdings Limited. Mr...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | no data | CN¥1.09m | 45% HK$ 2.4b | |
| Senior VP & Executive Director | 8.6yrs | CN¥193.00k | 0.90% HK$ 47.8m | |
| Senior VP & Executive Director | 8.6yrs | CN¥1.19m | 5.24% HK$ 277.6m | |
| Executive Director | no data | CN¥1.57m | 0.19% HK$ 10.1m | |
| Chief Financial Officer | 3.9yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | 3.5yrs | geen gegevens | geen gegevens | |
| Company Secretary | less than a year | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1789 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9.3yrs | CN¥1.09m | 45% HK$ 2.4b | |
| Senior VP & Executive Director | 9.3yrs | CN¥193.00k | 0.90% HK$ 47.8m | |
| Senior VP & Executive Director | 9.3yrs | CN¥1.19m | 5.24% HK$ 277.6m | |
| Executive Director | 8.8yrs | CN¥1.57m | 0.19% HK$ 10.1m | |
| Non-Executive Director | 8.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 7yrs | CN¥178.00k | geen gegevens | |
| Independent Non-Executive Director | 7yrs | CN¥178.00k | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
8.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1789 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).